SavedAdd your journal

Journals / Journal of Neurological Sciences (Turkish) / 2010 / Cilt: 27 - Sayı: 1

Alzheimer hastalığında beyin omurilik sıvısı ve serumda beta sekretaz aktivitesi

Cerebrospinal fluid and serum βeta secretase activities in Alzheimer's disease

Şermin GENÇ
Leyla İYİLİKÇİ
Erdem YAKA
Görsev YENER
Pages
69–74
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was also no statistical difference in serum β secretase activity between the patients (mean±S.E., 2298.9 ± 70.3) and the controls (mean±S.E., 2438.2 ± 119.4).Conclusions: In conclusion, these results indicate that beta-secretase activity is not changed in Alzheimer's disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to investigate β secretase activities in cerebrospinal fluid (CSF) and serum of patients with Alzheimer's disease (AD) as a possible biological marker in AD.Methods: The serum and the CSF samples were investigated in both patient and control groups.
📊
Key Findings & Data:For CSF analysis twelve patients diagnosed with ‘probable AD' according to DSM IV and NINCDS/ADRDA criteria and nine controls were studied.Results: There was no statistical difference in CSF β secretase activity between AD patients (mean±S.E., 343.8 ± 47.9) and the controls (mean±S.E., 409.6 ± 34.9).
💡
Conclusion & Impact:There was also no statistical difference in serum β secretase activity between the patients (mean±S.E., 2298.9 ± 70.3) and the controls (mean±S.E., 2438.2 ± 119.4).Conclusions: In conclusion, these results indicate that beta-secretase activity is not changed in Alzheimer's disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to investigate β secretase activities in cerebrospinal fluid (CSF) and serum of patients with Alzheimer's disease (AD) as a possible biological marker in AD.Methods: The serum and the CSF samples were investigated in both patient and control groups. For serum analysis, thirteen patients diagnosed with ‘probable AD' according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) and National Institute of Neurological Disorders and Stroke–Alzheimer Disease and Related Disorders (NINCDS/ADRDA) criteria and twelve controls were studied. For CSF analysis twelve patients diagnosed with ‘probable AD' according to DSM IV and NINCDS/ADRDA criteria and nine controls were studied.Results: There was no statistical difference in CSF β secretase activity between AD patients (mean±S.E., 343.8 ± 47.9) and the controls (mean±S.E., 409.6 ± 34.9). There was also no statistical difference in serum β secretase activity between the patients (mean±S.E., 2298.9 ± 70.3) and the controls (mean±S.E., 2438.2 ± 119.4).Conclusions: In conclusion, these results indicate that beta-secretase activity is not changed in Alzheimer's disease.

Özet

Amaç: Biz bu çalışmada beta sekretaz aktivitesini, Alzheimer hastalığı (AH) için olası bir biyolojik belirteç olarak, Alzheimer hastalarının beyin omurilik sıvılarında ve serumlarında araştırmayı amaçladık.Yöntem: Hasta ve kontrol gruplarının beyin omurilik sıvısı (BOS) ve serum örnekleri incelendi. Serum analizi için DSM IV ve NINCDS/ADRDA kriterlerine göre ‘olası AH' tanısı almış onüç hasta ve oniki kontrol alındı. BOS incelemesi için DSM IV ve NINCDS/ADRDA kriterlerine göre ‘olası AH' tanısı almış oniki hasta ve dokuz kontrol alındı.Bulgular: Alzheimer hastaları (Ortalama±S.H., 343.8 ± 47.9) ve kontrol grubu (Ortalama±S.H., 409.6 ± 34.9) arasında BOS beta sekretaz aktiviteleri açısından istatistiksel fark yoktu. Alzheimer hastaları (Ortalama±S.H., 2298.9 ± 70.3) ve kontrol grubu (Ortalama±S.H., 2438.2 ± 119.4 ) arasında serum beta sekretaz aktiviteleri açısından istatistiksel fark yoktu.Sonuç: Sonuç olarak bu rakamlar beta sekretaz aktivitesinin Alzheimer hastalığında değişmediğini göstermektedir.

🔖

Cite This Article

GENÇ, Ş., İYİLİKÇİ, L., YAKA, E., YENER, G. (2022). Alzheimer hastalığında beyin omurilik sıvısı ve serumda beta sekretaz aktivitesi. Journal of Neurological Sciences (Turkish), Cilt: 27 - Sayı: 1, 69–74. https://ajindex.com/articles/565421

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (IV-TR). 4th edn, text revised, Washington DC 2) Blass JP, Zemcov A. Alzheimer's disease: A metabolic systems degeneration? Neurochem Pathol 1984
  2. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc. Natl. Acad. Sci. U.S.A. 2000
  3. 97 (17): 9712–9717. 4) Fukumoto H, Cheung BS, Hyman BT, Irizarry MC Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002
  4. 1381–1389 5) Goedert, M., Crowther, R.A., Spillantini, M.G. Tau mutations cause frontotemporal dementias. Neuron 1998
  5. 955–958. 6) Gorham P, Bark N, Björkhem, Meaney S, Crisby M. Platelet Alpha- and Beta-Secretase Activities are not significantly affected by Dementia or Mild Cognitive Impairment in Swedish Patients. Curr Alzheimer Res. 2009 Dec 1. 7) Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992
  6. 359(6393):322–325. 8) Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol. 2004Jun
  7. 55(6):898-9 9) Johnston JA, Liu WW, Coulson DT, Todd S, Murphy S, Brennan S, Foy CJ, Craig D,Irvine GB, Passmore AP. Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol Aging. 2008 May
  8. 29(5):661-8. 10) Johnston JA, Liu WW, Todd SA, Coulson DT, Murphy S, Irvine GB, Passmore AP. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans. 2005 Nov
  9. 33(Pt 5):1096-100. 11) Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 2004
  10. 3632–3637. 12) Liu WW, Todd S, Craig D, Passmore AP, Coulson DT, Murphy S, Irvine GB, Johnston JA. Elevated platelet beta-secretase activity in mild cognitive impairment. Dement Geriatr Cogn Disord. 2007
  11. 24(6):464-8. 13) McKhann G, Drachman DA, Folstein M, Katzman R, Price DL, Stadlan EM. Clinical diagnosis of Alzheimer's disease—report of the NINCDS–ADRDA work gr